Fetzima Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Mechanism of Action
Fetzima Indications
Indications
Limitations of Use
Fetzima Dosage and Administration
Adult
Children
Fetzima Contraindications
Contraindications
Fetzima Boxed Warnings
Boxed Warning
Fetzima Warnings/Precautions
Warnings/Precautions
Increased risk of suicidal thoughts and behavior in children and young adults; monitor for clinical worsening and unusual changes. Suicidal ideation. Screen for bipolar disorder, mania, or hypomania prior to initiation. Monitor for serotonin syndrome; discontinue if occurs. Pre-existing hypertension, cardio- or cerebrovascular disease, or tachyarrhythmias. Monitor BP, HR prior to and during therapy; consider discontinuation or other treatment if elevation persists. Risk for bleeding events. Avoid in those with anatomically narrow angles. Obstructive urinary disorders. History of mania/hypomania. Seizure disorder. Renal impairment. Volume depleted. Hyponatremia (esp. elderly). Sexual dysfunction. Avoid abrupt cessation. Reevaluate periodically. Write ℞ for smallest practical amount. Pregnancy: see full labeling for effects on neonates in 3rd trimester. Nursing mothers: monitor infants.
Fetzima Pharmacokinetics
Absorption
Relative bioavailability: 92%. Median time to peak concentration (Tmax): 6–8 hours.
Distribution
Apparent volume of distribution: 387–473 L. Plasma protein bound: 22% over concentration range of 10–1000 ng/mL.
Elimination
Renal (58%). Mean apparent total clearance: 21–29 L/h. Half-life: ~12 hours.
Fetzima Interactions
Interactions
See Contraindications. Allow at least 14 days after MAOI discontinuation before starting levomilnacipran; allow at least 7 days after discontinuing levomilnacipran before starting an MAOI. Increased risk of serotonin syndrome with other serotonergic drugs (eg, other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Increased risk of bleeding with concomitant aspirin, NSAIDs, warfarin, and others that affect coagulation. Potentiated by strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, itraconazole, ritonavir); see Adult. Avoid alcohol. Caution with other CNS-active drugs, or drugs that can increase BP or HR.
Fetzima Adverse Reactions
Adverse Reactions
Fetzima Clinical Trials
See Literature
Fetzima Note
Not Applicable
Fetzima Patient Counseling
See Literature
Images
